Clinical trials: SGLT2 Inhibitor, open to volunteers
Heart Failure
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
- Trial name
- CONFIRMATION (NCT06024746)
- Testing
- Finerenone, Empagliflozin
- Where
- 140 sites in United States, Brazil and 6 more
- Volunteers
- 1,500 people
- Sponsor
- Colorado Prevention Center
Metabolic Syndrome
Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)
This study is a randomized, parallel-group, observer-masked clinical trial. A total of 200 obese participants with MetS will be enrolled.
- Trial name
- NCT06271200
- Testing
- Strategic lifestyle and drug interventions, Control
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Health Research Institutes, Taiwan
Lupus Nephritis, Chronic Kidney Diseases
SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD).
- Trial name
- NCT06155604
- Testing
- Dapagliflozin 10mg Tab, Standard maintenance therapy
- Where
- Hong Kong
- Volunteers
- 150 people
- Sponsor
- The University of Hong Kong
Metabolic Syndrome, Obesity & Overweight
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
We investigate the role of empagliflozin in the treatment of obesity in PLWH.
- Conditions
- Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)
- Trial name
- NCT07336797
- Testing
- Empagliflozin (oral)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Abdelrahman Mahmoud
Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF)
Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
Repaired Tetralogy of Fallot (rTOF) is the leading cause of congenital cyanotic heart disease worldwide, involving up to 7-10% of congenital heart disease.
- Conditions
- Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF), Pulmonary Regurgitation, Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor
- Trial name
- STEPS (NCT06668389)
- Testing
- SGLT2 inhibitor (Dapagliflozin 10mg)
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- The University of Hong Kong
Atrial Fibrillation (AF), Hypertension
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
Heart failure is the most important clinical endpoint event in atrial fibrillation (AF). Patients with AF complicated by heart failure have a significantly higher risk of all-cause mortality and cardiovascular mortality compared…
- Trial name
- NCT07482020
- Testing
- SGLT-2 inhibitors
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Huashan Hospital
Depression
Dapagliflozin in Depression
Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous.
- Trial name
- NCT07239011
- Testing
- Fluoxetine, Dapagliflozin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Chronic Kidney Disease
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with…
- Trial name
- NCT07348484
- Testing
- Empagliflozin
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Non-diabetic Chronic Kidney Disease
Vascular Effects of SGLT2i in Non-diabetic CKD
Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney disease (CKD) and heart failure and improves exercise tolerance regardless…
- Trial name
- EMPA-CKD (NCT07060417)
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- VA Office of Research and Development
Sepsis, Inflammation
Efficacy of SGLT2 Inhibitors in Adults With Sepsis
Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis.
- Conditions
- Sepsis, Inflammation, SGLT2 Inhibitors, Critically Ill
- Trial name
- NCT06473844
- Testing
- Empagliflozin 10 MG
- Where
- 3 sites in Hong Kong
- Volunteers
- 60 people
- Sponsor
- Hospital Authority, Hong Kong
Solid Tumor, SGLT 2 Inhibitors
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer
Revised version: Locally advanced or advanced solid tumors remain a major clinical challenge despite multimodal treatments, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy.
- Trial name
- SGLT2SOLID (NCT07703163)
- Testing
- Canagliflozin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- West China Hospital
Non-Alcoholic Fatty Liver Disease, NAFLD
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
- Trial name
- SLIDE (NCT03867487)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Fontan Circulation, Single Ventricle Heart Disease
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.
- Conditions
- Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT06762964
- Testing
- Dapagliflozin tablet
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Type 1 Diabetes Mellitus
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a type of medicine that help the kidneys get rid of extra sugar in the blood through urine.
- Trial name
- KETO-TRACK (NCT07225465)
- Testing
- FORXIGA
- Where
- 4 sites in Australia
- Volunteers
- 115 people
- Sponsor
- St Vincent's Hospital Melbourne
Type 2 Diabetic Kidney Disease
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
This study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria.
- Trial name
- NCT07775846
- Testing
- empagliflozin, Finerenone, Mazdutide
- Where
- China
- Volunteers
- 820 people
- Sponsor
- Huijie Zhang
Type 2 Diabetes
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
- Trial name
- START (NCT05345327)
- Testing
- Dapagliflozin, Metformin
- Where
- 8 sites in Australia, Sri Lanka
- Volunteers
- 994 people
- Sponsor
- The George Institute
Bipolar Disorder, Bipolar Depression
Empagliflozin Adjunctive Therapy in Bipolar Depression
Bipolar disorder is a long-term mental health condition that causes mood changes, with depressive episodes being the most frequent and disabling.
- Conditions
- Bipolar Disorder, Bipolar Depression, Insulin Resistance
- Trial name
- EMPA-BD (NCT07472920)
- Testing
- Empagliflozin (EMPA)
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo
Type 1 Diabetes, Type 2 Diabetes
Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors
The purpose of this research is to see how well a special education plan using continuous ketone monitoring (DGK) works to lower the risk of a condition called diabetic ketoacidosis (DKA) in people with type 1 diabetes (T1D)…
- Trial name
- KARMA (NCT07421518)
- Testing
- SGLT-2 inhibitor (Sotagliflozin), Insulin withdrawal test (IWT)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Myelodysplastic Syndromes (MDS), Anemia
Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes
This study is a prospective, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of dapagliflozin in improving anemia in patients with lower-risk myelodysplastic syndromes (MDS).
- Trial name
- DAPA-MDS1 (NCT07516847)
- Testing
- Dapagliflozin (10mg Tab)
- Volunteers
- 37 people
- Sponsor
- Seug yun Yoon, MD
Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease
Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)
The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women.
- Conditions
- Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
- Trial name
- STRONG (NCT06600178)
- Testing
- Brenzavvy (bexagliflozin), 20 mg Oral Tablet
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Virginia